Page last updated: 2024-11-13

astressin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID73350132
CHEMBL ID436726
CHEMBL ID2370918
MeSH IDM0331577

Synonyms (5)

Synonym
astressin b
bdbm50119602
chembl436726
d l s d-phe his l l r k nleu i e i e k q e k e k glu q a lys n n r l l l d t i-nh2(calphameleu)(cyclo28-31)
CHEMBL2370918

Research Excerpts

Treatment

Astressin B treatment prevented luteal LH but not lutean progesterone decrease during the treatment cycle. Pretreatment with astressinB prevented the decrease.

ExcerptReferenceRelevance
"Astressin B treatment prevented luteal LH but not luteal progesterone decrease during the treatment cycle and restored normal progesterone secretion during the two posttreatment cycles."( Astressin B, a corticotropin-releasing hormone receptor antagonist, accelerates the return to normal luteal function after an inflammatory-like stress challenge in the rhesus monkey.
Ferin, M; Rivier, J; Vulliemoz, N; Xia-Zhang, L; Xiao, E, 2007
)
2.5
"Pretreatment with astressin B prevented the decrease."( Astressin B, a nonselective corticotropin-releasing hormone receptor antagonist, prevents the inhibitory effect of ghrelin on luteinizing hormone pulse frequency in the ovariectomized rhesus monkey.
Ferin, M; Rivier, J; Vulliémoz, NR; Xia-Zhang, L; Xiao, E, 2008
)
2.11
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID54126Compound was evaluated for affinity towards Corticotropin releasing factor receptor 2 expressing tissues such as Choroid plexus, blood vessels2002Journal of medicinal chemistry, Oct-10, Volume: 45, Issue:21
Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists.
AID53981Compound was evaluated for affinity towards Corticotropin releasing factor receptor 1 expressing tissues such as Cortex, cerebellum2002Journal of medicinal chemistry, Oct-10, Volume: 45, Issue:21
Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (2.63)18.2507
2000's24 (63.16)29.6817
2010's13 (34.21)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.14 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index6.14 (4.65)
Search Engine Demand Index61.30 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (29.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.63%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other37 (97.37%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]